Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Sweden / NCT05309850
Recruiting Not applicable

Primary Prevention With the Lifestyle Tool

NCT05309850 · tracked via the Priya Life Science Sweden tracker
Sponsor
Region Skane
Phase
Not applicable
Started
2022-04-05
Last updated
2025-07-16

Condition(s) studied

Cardiovascular DiseasesType 2 Diabetes

Investigational drug(s) / intervention(s)

Lifestyle tool

Lifestyle tool: Regular use of the digital Lifestyle tool

Study summary

In this study participants will be randomized to use a digital lifestyle tool over three years or to a control group without access to the tool. The investigators will prospectively via clinical registries follow the incidence and development of type 2 diabetes and cardiovascular disease in those using the tool regularly and those in the control group.

Eligibility

Sex
ALL
Min age
35 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * informed consent * Age above 35 years Exclusion Criteria: * type 1 diabetes, MODY or secondary diabetes * conditions or treatments that in the judgement of the Investigator could affect the study evaluation * connection with the study team, funders, authorities, universities or other public or private bodies in such a way that specific interests in the study outcomes could be suspected.

Primary outcome measure(s)

  • Incidence of major adverse cardiovascular event — 3 years
    Incidence of major adverse cardiovascular event, defined as cardiovascular death, myocardial infarction, stroke, or hospitalization for heart failure compared between participants regularly using the tool and on usual care.
  • Incidence of type 2 diabetes — 3 yars
    Incidence of type 2 diabetes defined as random plasma glucose \>11.1 mmol/L or fasting glucose \>7.0 mmol/L or HbA1C ≥6.5% compared between participants regularly using the tool and on usual care.

Trial sites (1)

FacilityCityRegionStatus
Skane University Hospital Malmö Sweden Recruiting

More Region Skane trials in Sweden

Sustainable Hypertension Management in Primary Health Care in Sweden Recruiting
Biomarkers After Out-of-hospital Cardiac Arrest- a STEPCARE Substudy Active, not recruiting
Comparison of Cloxacillin and Benzylpenicillin in Penicillin Susceptible S. Aureus Bacteraemia Recruiting
The Study Tests if Preoperative Dental Screening is Superior to no Preoperative Dental Screening in Improving the Outcome of Patients Undergoing Surgical Cardiac Valve Replacement or Transcatheter Cardiac Valve Implantation. Recruiting
Evaluation of Three Tests to Assess Social Cognition in Huntington Disease Recruiting

Other trials for the same condition

The Causal Effect of Bariatric Surgery on Cardiovascular Disease and Mortality Recruiting
Prospective Urban Rural Epidemiology Study Recruiting
Evaluation of Cascade Screening for Elevated Lipoprotein(a) Active, not recruiting
An Open Prospective Longitudinal Pulmonary-cardiovascular Cohort Study Enrolling by invitation
A Digital Lifestyle Intervention in Primary Healthcare to Prevent Cardiovascular Disease Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05309850 on ClinicalTrials.gov ↗ ← All trials in Sweden